Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 14;21(18):6718.
doi: 10.3390/ijms21186718.

Recent Advances in Cell-Based Therapies for Ischemic Stroke

Satoshi Suda  1 , Chikako Nito  1 , Shoji Yokobori  2 , Yuki Sakamoto  1 , Masataka Nakajima  1 , Kota Sowa  1 , Hirofumi Obinata  2 , Kazuma Sasaki  2 , Sean I Savitz  3 , Kazumi Kimura  1
Affiliations
Review

Recent Advances in Cell-Based Therapies for Ischemic Stroke

Satoshi Suda et al. Int J Mol Sci. .

Abstract

Stroke is the most prevalent cardiovascular disease worldwide, and is still one of the leading causes of death and disability. Stem cell-based therapy is actively being investigated as a new potential treatment for certain neurological disorders, including stroke. Various types of cells, including bone marrow mononuclear cells, bone marrow mesenchymal stem cells, dental pulp stem cells, neural stem cells, inducible pluripotent stem cells, and genetically modified stem cells have been found to improve neurological outcomes in animal models of stroke, and there are some ongoing clinical trials assessing their efficacy in humans. In this review, we aim to summarize the recent advances in cell-based therapies to treat stroke.

Keywords: angiogenesis; clinical trial; inflammation; neurogenesis; stem cell; stroke.

PubMed Disclaimer

Conflict of interest statement

Satoshi Suda received research funding from the All Japan Coffee Association, and lecture fees from Eisai Co., Ltd. Chikako Nito received research funding from the Kaneka Co., Ltd. Kazumi Kimura received lecture fees from Bristol-Myers Squibb Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Bayer Healthcare Co., Ltd. and Daiichi Sankyo Co., Ltd., and research funding from Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., and Teijin Pharma Co., Ltd.

Figures

Figure 1
Figure 1
Overview of proposed mechanisms of cell-based stroke therapies. Engrafted therapeutic cells exert neuro- and vaso-protective effects through secretion of various growth factors and systemic inflammation modulation. MNCs, marrow mononuclear cells, BMSCs, bone marrow mesenchymal stem cells; DPSCs, dental pulp stem cells; NSCs, neural stem cells; iPSCs, induced pluripotent stem cells; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; BDNF, brain-derived neurotrophic factor; GDNF, glial cell-derived neurotrophic factor; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-2, interleukin 2; IFN-γ, interferon gamma; TNF-α, tumor necrosis factor alpha.
See this image and copyright information in PMC

References

    1. Bang O.Y., Lee J.S., Lee P.H., Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann. Neurol. 2005;57:874–882. doi: 10.1002/ana.20501. - DOI - PubMed
    1. Bhatia V., Gupta V., Khurana D., Sharma R.R., Khandelwal N. Randomized Assessment of the Safety and Efficacy of Intra-Arterial Infusion of Autologous Stem Cells in Subacute Ischemic Stroke. AJNR Am. J. Neuroradiol. 2018;39:899–904. doi: 10.3174/ajnr.A5586. - DOI - PMC - PubMed
    1. Hess D.C., Wechsler L.R., Clark W.M., Savitz S.I., Ford G.A., Chiu D., Yavagal D.R., Uchino K., Liebeskind D.S., Auchus A.P., et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:360–368. doi: 10.1016/S1474-4422(17)30046-7. - DOI - PubMed
    1. Honmou O., Houkin K., Matsunaga T., Niitsu Y., Ishiai S., Onodera R., Waxman S.G., Kocsis J.D. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011;134:1790–1807. doi: 10.1093/brain/awr063. - DOI - PMC - PubMed
    1. Levy M.L., Crawford J.R., Dib N., Verkh L., Tankovich N., Cramer S.C. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke. 2019;50:2835–2841. doi: 10.1161/STROKEAHA.119.026318. - DOI - PubMed

Grants and funding